Shares of Apellis Pharmaceuticals, Inc. (APLS) are falling more than 21 percent Thursday morning after the company said it expects the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to give a negative opinion on its marketing authorization application for Pegcetacoplan to treat geographic atrophy.
Geographic atrophy, an advanced form of dry age-related macular degeneration (AMD), causes central vision loss.
CHMP is expected to provide its opinion on Pegcetacoplan at its next meeting scheduled between January 22 and 25.
APLS, currently at $49.56, has traded in the range of $19.83 - $94.75 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.